Furthermore, 68Ga-prostate-specific membrane antigen (PSMA) PET/CT has been shown to improve accuracy over conventional CT for staging of pelvic nodal disease in patients with high-risk prostate cancer [23], although PSMA-PET has limited sensitivity ≤ 50% for micrometastases < 4 mm [24, 25]. This evidence concerns the gene FOLH1 and prostate cancer.